/PRNewswire/ BIORCHESTRA is a leading RNA therapeutics company whose lead programs focus on neurodegenerative diseases using its proprietary RNA-based drug.
SEOUL, South Korea, Feb. 23, 2022 /PRNewswire/ BIORCHESTRA is a leading RNA therapeutics company whose lead programs focus on neurodegenerative diseases using its proprietary RNA-based drug and drug delivery platforms. Today, BIORCHESTRA announced the completion of its 45 million USD (54 billion KRW) Series C Fundraising as of 22nd February 2022. Participants in the Series C were.
/PRNewswire/ BIORCHESTRA is a leading RNA therapeutics company whose lead programs focus on neurodegenerative diseases using its proprietary RNA-based drug.